Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia

Lancet

Volumn 350, Issue 9080, 1997, Pages 767-771

  Hongeng, Suradej ^a   Krance, Robert A ^a,b   Bowman, Laura C ^a,b   Srivastava, Deo K ^a   Cunningham, John M ^a   Horwitz, Edwin M ^a   Brenner, Malcolm K ^a,b   Heslop, Helen E ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DONOR; FEMALE; GRAFT PATENCY; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 0030930329     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03098-5     Document Type: Article

References (35)

1. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-47.
2. Howard MR, Hows JM, Gore SM, et al. Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. Transplantation 1990; 49: 547-53.
3. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA identical siblings. J Clin Oncol 1997; 15: 1767.
4. Anderson JE, Anaasetti C, Appelbaum FR, et al. Unrelated donor bone marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93: 59-67.
5. Davies SM, Ramsay NKC, Haake RJ, et al. Comparison of engraftment in recipients of matched sibling or unrelated donor allografts. Bone Marrow Transplant 1994; 13: 54-57.
6. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-50.
7. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer donors: a comparison of complications in the first two years. Ann Intern Med 1993; 119: 207-14.
8. Kook H, Goldman F, Padley D, et al. Reconstruction of the immune system after unrelated or partially matched T cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996; 88: 1089-97.
9. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 1995; 86: 1228-34.
10. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-41.
11. Anasetti C, Etzioni R, Petersdorf EW, Martin PJ, Hansen JA. Marrow transplantation from unrelated volunteer donors. Annu Rev Med 1995; 46: 169-79.
12. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-07.
13. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324: 1005-11.
14. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
15. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-55.
16. Krance R, Heslop HE, Mahmoud H, et al. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogenic BMT from HLA-identical sibling donors. Bone Marrow Transplant 1993; 11: 33-36.
17. Koehler M, Hurwitz CA, Krance RA, et al. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant 1994; 13: 571-75.
18. Prentice HG, Blacklock HA, Janossy F, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancer 1984; i: 472-76.
19. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295.
20. Heslop HE, Benaim E, Brenner MK, et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet 1995; 346: 805-06.
21. Heslop HE, Brenner MK, Rooney CM, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 1994; 5: 381-97.
22. Oakhill A, Pamphilon DH, Potter MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-78.
23. Balduzzi A, Gooley T, Anasetti C, et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-56.
24. Casper J, Camitta B, Truitt R, et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2354-63.
25. Gamis AS, Haake R, McGlave P, Ramsay NKC. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993; 11: 834-38.
26. Hows J, Bridle BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-80.
27. Beatty PG, Kollman C, Howe CW. Unrelated-donor marrow transplantation: the experience of the NMDP. Clin Transpl 1995: 271-73.
28. Spieser DE. Tiercy JM, Rufer N, et al. High resolution HLA typing associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455-62.
29. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996; 93: 15358-63.
30. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HTA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-13.
31. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-30.
32. Lucas K, Small T, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-603.
33. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-66.
34. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88: 795-802.
35. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell depleted haploidentical "three loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow incoculum. Blood 1994; 84: 3948-55.